My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

34.83 +0.18 (+0.52%)
Streaming Delayed Price Updated: 10:17 AM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Collegium Pharmaceutical, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day with a breakdown of the biggest pre-market stock movers investors will want to watch on Tuesday! 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Collegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Analyst Sees This 'Specialty Pharma' Stock Stuck Until Prescription Trends Improve
 
Via Benzinga
Recap: Collegium Pharmaceutical Q1 Earnings
Collegium Pharmaceutical (NASDAQ:COLL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Why Collegium Pharmaceutical's Shares Are Trading Higher Today
 
Via Benzinga
Collegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Provides 2023 Financial Guidance
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Appeals Court Affirms Validity of Collegium’s Belbuca® Patents
Ruling bars ANDA filer Alvogen from entering market until 2032 patent expiry 
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Participate in Piper Sandler 34th Annual Healthcare Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Reports Third Quarter 2022 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Report Third Quarter 2022 Financial Results on November 3, 2022
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022
  
Via Benzinga
7 Micro-Cap Stocks to Take a Chance on Now
Despite (or because of) their size, some micro-cap stocks, have good value and are overlooked and should be considered by investors. 
Via InvestorPlace
A Preview Of Collegium Pharmaceutical's Earnings
Collegium Pharmaceutical (NASDAQ:COLL) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
What Defines a Value Stock? 
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E... 
Via Benzinga
Analyst Ratings For Collegium Pharmaceutical
Over the past 3 months, 4 analysts have published their opinion on Collegium Pharmaceutical (NASDAQ:COLL) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
JP Morgan raised Ralph Lauren Corporation (NYSE: RL) price target from $137 to $142. Ralph Lauren shares rose 1.2% to $124.00 in pre-market trading. 
Via Benzinga
BDSI Stock Alert: The Deal Sending Little-Known BioDelivery Skyrocketing Today
Today, a big takeover announcement has sent shares of BioDelivery and BDSI stock soaring more than 50% on investor enthusiasm for this deal. 
Via InvestorPlace
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
32 Stocks Moving In Monday's Mid-Day Session
Gainers BioDelivery Sciences International, Inc. (NASDAQ: BDSI) shares jumped 51.9% to $5.53. Collegium Pharmaceutical will acquire BioDelivery Sciences International at $5.60... 
Via Benzinga
52 Biggest Movers From Yesterday
Gainers BioDelivery Sciences International, Inc. (NASDAQ: BDSI) shares climbed 52.8% to close at $5.56 on Monday. Collegium Pharmaceutical will acquire BioDelivery Sciences... 
Via Benzinga
Collegium Pharma Broadens Its Pain Portfolio With $600M BioDelivery Sciences Deal
Collegium Pharmaceutical Inc (NASDAQ: COLL) will acquire BioDelivery Sciences International Inc (NASDAQ: BDSI) at $5.60 per share in an all-cash transaction,... 
Via Benzinga
A Look Into Healthcare Sector Value Stocks
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E... 
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
Collegium Pharmaceutical, inc (COLL) Q3 2021 Earnings Call Transcript
COLL earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.